Hidekazu Nishikii

Hidekazu Nishikii

Auto-generated profile, based on publicly available information

Hidekazu Nishikii

Department of Hematology, University of Tsukuba Hospital; Department of Transfusion Medicine, University of Tsukuba Hospital; Department of Hematology, Institute of Medicine, University of Tsukuba

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2023 in Nature
Verified
Journal Article
Closed access
PDF file
MSMasatoshi Sakurai
Masatoshi Sakurai
KIKantaro Ishitsuka
Kantaro Ishitsuka
RIRyoji Ito
Ryoji Ito
AWAdam C. Wilkinson
Adam C. Wilkinson
TKTakaharu Kimura
Takaharu Kimura
SYSatoshi Yamazaki
Satoshi Yamazaki

11 August 2016 in Blood
Verified
Journal Article
Open access
PDF file
APAntonio Pierini
Antonio Pierini
WSWilliam Strober
William Strober
CMCaitlin Moffett
Caitlin Moffett
JBJeanette Baker
Jeanette Baker
HNHidekazu Nishikii
Hidekazu Nishikii
RNRobert S. Negrin
Robert S. Negrin
Key Points: TNF-α produced during aGVHD is a strong and selective activator of CD4+CD25+FoxP3+ Tregs. In vitro TNF-α priming enhances CD4+CD25+FoxP3+ Treg proliferation and their ability to protect from GVHD.

15 December 2016 in Blood
Verified
Journal Article
Open access
PDF file
HNHidekazu Nishikii
Hidekazu Nishikii
BKByung-Su Kim
Byung-Su Kim
YYYasuhisa Yokoyama
Yasuhisa Yokoyama
YCYan Chen
Yan Chen
JBJeanette Baker
Jeanette Baker
RNRobert S. Negrin
Robert S. Negrin
Key Points: After DR3 activation, CD4+Foxp3+ regulatory T cells showed a distinct immune phenotype and function in acute GVHD. Prophylactic treatment with agonistic DR3 antibody to recipient mice abrogated the lethal acute GVHD in a time-dependent manner.

6 July 2017 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
HNHidekazu Nishikii
Hidekazu Nishikii
NKNaoki Kurita
Naoki Kurita
SCShigeru Chiba
Shigeru Chiba
Summary: Megakaryocytes (Mgks) are terminally differentiated blood cells specified to produce platelets, whereas hematopoietic stem cells (HSCs) are the most undifferentiated blood cells that retain multipotency to produce all kinds of blood cells. As such, these two cell types reside at the bottom and the top of the hematopoietic hierarchy, respectively. In spite of this distance, they share several important cell surface molecules as well as transcription factors. In the conventional step-wise differentiation model, HSCs gradually lose their self-renewal capacity and differentiate into multipotent progenitors (MPPs), which is the first branch point of myeloid and lymphoid lineage. In this model, common myeloid progenitors can differentiate into bipotent Mgk/erythroid progenitors (MEPs), and MEPs eventually differentiate into unipotent mature Mgks. However, it has been recently reported that a subpopulation within the HSC and MPP compartments demonstrates an Mgk-biased differentiation potential. These reports imply that revisions to the HSC-to-Mgk differentiation pathway should be discussed. In this review, we summarize recent findings about Mgk differentiation from HSCs and discuss future directions in this research field.

21 August 2013 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
TSTatsuhiro Sakamoto
Tatsuhiro Sakamoto
NONaoshi Obara
Naoshi Obara
KNKurita Naoki
Kurita Naoki
MSMamiko Sakata-Yanagimoto
Mamiko Sakata-Yanagimoto
HNHidekazu Nishikii
Hidekazu Nishikii
SCShigeru Chiba
Shigeru Chiba

8 March 2023 in Leukemia
Verified
Journal Article
Open access
PDF file
YKYusuke Kiyoki
Yusuke Kiyoki
TKTakayasu Kato
Takayasu Kato
SKSakura Kito
Sakura Kito
TMTakashi Matsuzaka
Takashi Matsuzaka
SMShin Morioka
Shin Morioka
SCShigeru Chiba
Shigeru Chiba